Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: A systematic simulation analysis

Supportive Care in Cancer

Volumn 19, Issue 10, 2011, Pages 1657-1665

  Imataki, Osamu ^a   Kubota, Yoshitsugu ^b   Ohnishi, Hiroaki ^a   Kitanaka, Akira ^a   Ishida, Toshihiko ^a   Tanaka, Terukazu ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Antifungal prophylaxis; Hematological malignancy; Medical cost

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO;

ARTICLE; COST BENEFIT ANALYSIS; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFECTION PREVENTION; ISCHEMIA; JAPAN; MYCOSIS; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SENSITIVITY ANALYSIS; SEPSIS; SIMULATION; TREATMENT FAILURE;

ADULT; ANTIFUNGAL AGENTS; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; DRUG COSTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; JAPAN; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 80052429797     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0998-3     Document Type: Article

References (31)

1. KA Marr 2001 Antifungal prophylaxis in hematopoietic stem cell transplant recipients Oncology (Williston Park) 15 11 SUPPL. 9 15 19 1:STN:280: DC%2BD38%2FjtVyksw%3D%3D (Pubitemid 33739265)
2. OA Cornely AJ Ullmann M Karthaus 2003 Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies Blood 101 3365 3372 12393455 10.1182/blood-2002-05-1356 1:CAS:528:DC%2BD3sXjs1aqs7w%3D (Pubitemid 36857916)
3. TJ Walsh P Pappas DJ Winston National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al. 2002 Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 225 234 11807146 10.1056/NEJM200201243460403 1:CAS:528:DC%2BD38XmslGgsg%3D%3D (Pubitemid 34438861)
4. TJ Walsh H Teppler GR Donowitz, et al. 2004 Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 1391 1402 15459300 10.1056/NEJMoa040446 1:CAS:528:DC%2BD2cXotVOrsro%3D (Pubitemid 39288165)
5. ER Kuse P Chetchotisakd CA da Cunha Micafungin Invasive Candidiasis Working Group 2007 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 1519 1527 17482982 10.1016/S0140-6736(07)60605-9 1:CAS:528:DC%2BD2sXkvFGmt7c%3D (Pubitemid 46670281)
6. O Uzun EJ Anaissie 1995 Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal Blood 86 2063 2072 7662953 1:CAS:528:DyaK2MXotVShsbc%3D
7. Working Group of the invasive fungal infection guideline advisory council (2007) Guidelines of diagnoses and treatment for the invasive fungal infections. Kyowa Kikaku KK, Tokyo
8. O Penack S Schwartz P Martus, et al. 2006 Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial Ann Oncol 17 1306 1312 16766594 10.1093/annonc/mdl128 1:STN:280:DC%2BD28vkvVOrtQ%3D%3D (Pubitemid 44288223)
9. SM Kelsey JM Goldman S McCann BA Oppenheim GJ Mufti, et al. 1999 Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study Bone Marrow Transplant 23 163 168 10197802 10.1038/sj.bmt.1701543 1:STN:280:DyaK1M3htFKmuw%3D%3D (Pubitemid 29048218)
10. Y Ito K Ohyashiki I Yoshida, et al. 2007 The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study Int J Hematol 85 121 127 17321989 10.1532/IJH97.06079 1:CAS:528:DC%2BD2sXjvV2rtL4%3D (Pubitemid 46365548)
11. A Glasmacher O Cornely AJ Ullmann Itraconazole Research Group of Germany, et al. 2006 An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia J Antimicrob Chemother 57 317 325 16339606 10.1093/jac/dki440 1:CAS:528: DC%2BD28XovVGgsg%3D%3D (Pubitemid 43160176)
12. PC Huijgens AM Simoons-Smit AC van Loenen, et al. 1999 Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology J Clin Pathol 52 376 380 10560360 10.1136/jcp.52.5.376 1:STN:280: DC%2BD3c%2FisVWmsg%3D%3D (Pubitemid 29200032)
13. OA Cornely J Maertens DJ Winston, et al. 2007 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348 359 17251531 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D (Pubitemid 46148777)
14. JA van Burik V Ratanatharathorn DE Stepan National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al. 2004 Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 1407 1416 15546073 10.1086/422312 (Pubitemid 39518200)
15. C Lass-Flörl E Gunsilius G Gastl, et al. 2003 Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution Ann Hematol 82 565 569 14504812 10.1007/s00277-003-0666- 5 (Pubitemid 37220674)
16. GN Mattiuzzi E Estey I Raad, et al. 2003 Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome Cancer 97 450 456 12518369 10.1002/cncr.11094 1:CAS:528:DC%2BD3sXhtFGltLw%3D (Pubitemid 36133812)
17. M Boogaerts J Maertens A van Hoof, et al. 2001 Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients J Antimicrob Chemother 48 97 103 11418517 10.1093/jac/48.1.97 1:CAS:528:DC%2BD3MXlsVegtbs%3D (Pubitemid 32684731)
18. JL Harousseau AW Dekker A Stamatoullas-Bastard, et al. 2000 Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B Antimicrob Agents Chemother 44 1887 1893 10858349 10.1128/AAC.44.7.1887-1893. 2000 1:CAS:528:DC%2BD3cXksVKksb4%3D (Pubitemid 30422943)
19. M Nucci I Biasoli T Akiti, et al. 2000 A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients Clin Infect Dis 30 300 305 10671332 10.1086/313654 1:CAS:528:DC%2BD3cXit1Khtb0%3D (Pubitemid 30131537)
20. F Menichetti AD Favero P Martino, et al. 1999 Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial Clin Infect Dis 28 250 255 10064240 10.1086/515129 1:CAS:528:DyaK1MXhtlKlu7k%3D (Pubitemid 29241212)
21. C Rotstein EJ Bow M Laverdiere, et al. 1999 Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian fluconazole prophylaxis study group Clin Infect Dis 28 331 340 10064252 10.1086/515128 1:CAS:528:DyaK1MXhtlKksrw%3D
22. GR Morgenstern AG Prentice HG Prentice, et al. 1999 A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group Br J Haematol 105 901 911 10554799 10.1046/j.1365-2141.1999.01465.x 1:CAS:528:DyaK1MXksFylsL8%3D (Pubitemid 29309095)
23. E Robenshtok A Gafter-Gvili E Goldberg, et al. 2007 Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis J Clin Oncol 25 5471 5489 17909198 10.1200/JCO.2007.12.3851 1:CAS:528:DC%2BD1cXnvVChsQ%3D%3D (Pubitemid 350232225)
24. R de Vries S Daenen K Tolley, et al. 2008 Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections Pharmacoeconomics 26 75 90 18088160 10.2165/00019053-200826010-00007
25. R van Gool 2001 The cost of treating systemic fungal infections Drugs 61 SUPPL. 1 49 56 11219550 10.2165/00003495-200161001-00005 (Pubitemid 32151112)
26. M Pignone S Saha T Hoerger, et al. 2005 Challenges in systematic reviews of economic analyses Ann Intern Med 142 12 Pt 2 1073 1079 15968032 (Pubitemid 40847710)
27. J Maertens M Boogaerts 2005 The place for itraconazole in treatment J Antimicrob Chemother 56 SUPPL. 1 i33 i38 16120632 10.1093/jac/dki222 1:CAS:528:DC%2BD2MXpsVakurk%3D (Pubitemid 41236088)
28. CDC, Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation (2001) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy 3:41-54
29. O Imataki M Kami SW Kim 2004 A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan Bone Marrow Transplant 33 1173 1179 15094754 10.1038/sj.bmt.1704526 1:STN:280:DC%2BD2c3ot1ymsg%3D%3D (Pubitemid 38961473)
30. JL Goodman DJ Winston RA Greenfield, et al. 1992 A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation N Engl J Med 326 845 851 1542320 10.1056/NEJM199203263261301 1:STN:280:DyaK387nvVaqtw%3D%3D
31. MA Slavin B Osborne R Adams, et al. 1995 Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study J Infect Dis 171 1545 1552 7769290 10.1093/infdis/171.6.1545 1:STN:280:DyaK2M3oslSntQ%3D%3D